CDEK by Data4ThePeople
Sign in Sign up
← All drugs Report issue

sugammadex

Trade name: bridion

Small moleculeapproved

Approved

Dec 15, 2015

Sugammadex (ORG 25969) is a cyclodextrin derivative was synthesized as synthetic receptor (or host molecule) for neuromuscular blockers (rocuronium and vecuronium). It forms a complex with the neuromuscular blocking agents rocuronium and vecuronium, and it reduces the amount of neuromuscular blocking agent available to bind to nicotinic cholinergic receptors in the neuromuscular junction. This results in the reversal of neuromuscular blockade induced by rocuronium and vecuronium. The clinical use of sugammadex promises to eliminate many of the shortcomings in current anesthetic practice with regard to antagonism of rocuronium and other aminosteroid muscle relaxants. Sugammadex is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults undergoing surgery. — NCATS

Clinical trial activity

231 trials · 145 clinical orgs · 13 marketing orgs

Phase 1
11
Phase 2
56
Phase 3
39
Phase 4
108

Earliest trial started Dec 1, 2002 (NCT03519854)

Timeline

2000s

  1. Jan 1, 2002

    Merck — Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2005

    Merck — Earliest Phase 3 Sponsor(trial)

  3. Jan 1, 2009

    Merck — Earliest Phase 1 Sponsor(trial)

2010s

  1. Dec 15, 2015

    Merck — Earliest FDA Approval

  2. Dec 15, 2015

    Organon — NDA Secondary Org

  3. Dec 15, 2015

    Merck — NDA Organization

  4. Dec 15, 2015

    Merck — Marketing Organization

2020s

  1. Sep 17, 2021

    Tamarang — Marketing Organization

  2. Mar 8, 2022

    Sandoz — Marketing Organization

  3. May 10, 2022

    Sun Pharmaceuticals — Marketing Organization

  4. Sep 14, 2022

    Zydus Discovery DMCC — Marketing Organization

  5. Oct 13, 2022

    Mylan — Marketing Organization

  6. Jan 20, 2023

    Mankind Pharma — Marketing Organization

  7. Mar 20, 2023

    Shandong Lanjin Pharmaceuticals Co.,Ltd — Marketing Organization

  8. Jun 9, 2023

    Aspiro — Marketing Organization

  9. Jun 23, 2023

    Novartis — Marketing Organization

  10. Jun 27, 2025

    Hikma — Marketing Organization

  11. Aug 5, 2025

    B. Braun — Marketing Organization

Indications

Approved for

Studied for

Mechanism of action

  • VecuroniumSEQUESTERING AGENT

    Vecuronium sequestering agent

  • RocuroniumSEQUESTERING AGENT

    Rocuronium sequestering agent

Approval history

  • approvedPriority reviewDec 15, 2015

Chemistry & pharmacology

Loading structure…

SMILES

O=C(O)CCSC[C@H]1O[C@@H]2O[C@H]3[C@H](O)[C@@H](O)[C@@H](O[C@H]4[C@H](O)[C@@H](O)[C@@H](O[C@H]5[C@H](O)[C@@H](O)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@@H](O[C@H]7[C@H](O)[C@@H](O)[C@@H](O[C@H]8[C@H](O)[C@@H](O)[C@@H](O[C@H]9[C@H](O)C(O)[C@@H](O[C@H]1[C@H](O)[C@H]2O)O[C@@H]9CSCCC(=O)O)O[C@@H]8CSCCC(=O)O)O[C@@H]7CSCCC(=O)O)O[C@@H]6CSCCC(=O)O)O[C@@H]5CSCCC(=O)O)O[C@@H]4CSCCC(=O)O)O[C@@H]3CSCCC(=O)O
Mol. weight
2002.18 g/mol
Chirality
Racemic Mixture
Inorganic
No
Polymer
No
Delivery
Parenteral
Availability
Prescription Only

Oral

No

Parenteral

Yes

Topical

No

First in class

Sources

Also known as

  • 6-perdeoxy-6-per(2-carboxyethyl)thio-gamma-cyclodextrin sodium salt
  • bridion
  • bridion
  • bridion
  • bridion
  • bridion
  • org 25969
  • org 25969
  • org-25969
  • org-25969
  • sugammadex
  • sugammadex
  • sugammadex
  • sugammadex
  • sugammadex
  • sugammadex
  • sugammadex
  • sugammadex
  • sugammadex
  • sugammadex
  • sugammadex sodium
  • sugammadex sodium
  • sugammadex sodium
  • sugammadex sodium
  • sugammadex sodium
  • suggamadex

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07271875Phase 3Jan 1, 2026Xijing Hospital
NCT07309393N/ADec 30, 2025Huazhong University of Science and Technology
NCT07253428N/AOct 30, 2025Ain Shams University
NCT07203287Phase 4Aug 26, 2025University of Texas, Galveston
NCT06962007N/AMay 1, 2025Wonkwang University
NCT06634355N/ADec 31, 2024Katholieke Universiteit Leuven
NCT06678451N/ADec 31, 2024Shanxi Bethune Hospital
NCT06794450Phase 1/Phase 2 (Phase 2)Nov 5, 2024Padjadjaran University
NCT06575036Phase 2Sep 15, 2024Seoul National University
NCT06982092Phase 1Aug 26, 2024Ain Shams University
NCT06436768N/AJun 1, 2024Capital Medical University, Nanjing Medical University
NCT06398899N/AMay 1, 2024National Taiwan University
NCT06334562N/AMay 1, 2024Zhejiang University
NCT06225466Phase 4Apr 10, 2024Merck, The University of Texas, Dallas
NCT06136585N/AJan 1, 2024Merck, The Cleveland Clinic
NCT06228092Phase 4Dec 4, 2023University of Copenhagen
NCT05985343Phase 4Dec 1, 2023The Cleveland Clinic
NCT06112353Phase 4Nov 30, 2023Merck, University of California, Irvine
NCT05751603N/AOct 3, 2023Ajou University
NCT06035757Phase 4Sep 15, 2023Konkuk University
Showing 20 of 231 trials
Page 1 / 12

Organizations

Research & Development (145)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
MerckFor profit734152002
Seoul National UniversityAcademic/Hospital121232014
Yonsei UniversityAcademic/Hospital7712013
Ajou UniversityAcademic/Hospital5512018
University of CopenhagenAcademic/Hospital5512009
Korea UniversityAcademic/Hospital4422015
People's Liberation Army of ChinaGovernment4412019
The Cleveland ClinicAcademic/Hospital4422017
The University of Texas, DallasAcademic/Hospital4332016
University of AthensAcademic/Hospital4422010
Ain Shams UniversityAcademic/Hospital3322017
Capital Medical UniversityAcademic/Hospital3312020
OLV Hospital, Aalst, BelgiumAcademic/Hospital3022012
Onze Lieve Vrouw HospitalAcademic/Hospital3322012
Palacky UniversityAcademic/Hospital3212012
Stony Brook UniversityAcademic/Hospital3312016
University of Texas at HoustonAcademic/Hospital3312017
West Virginia UniversityAcademic/Hospital3322017
Ankara Yildirim Beyazıt UniversityAcademic/Hospital2222012
Cairo UniversityAcademic/Hospital2112014
145 organizations
Page 1 / 8

Marketing (17)

OrganizationOrg typeRelationshipDate
AspiroFor profitMKTGJun 9, 2023
B. BraunFor profitMKTGAug 5, 2025
HikmaFor profitMKTGJun 27, 2025
Mankind PharmaFor profitMKTGJan 20, 2023
MerckFor profitNDADec 15, 2015
MerckFor profitMKTGDec 15, 2015
MylanFor profitMKTGOct 13, 2022
MylanFor profitSYNJun 15, 2023
NovartisFor profitMKTGJun 23, 2023
OrganonFor profitNDA2Dec 15, 2015
SandozFor profitMKTGMar 8, 2022
SandozFor profitSYNJun 23, 2023
Shandong Lanjin Pharmaceuticals Co.,LtdFor profitMKTGMar 20, 2023
Sun PharmaceuticalsFor profitMKTGMay 10, 2022
TamarangFor profitMKTGSep 17, 2021
Zydus Discovery DMCCFor profitMKTGSep 14, 2022
Zydus Discovery DMCCFor profitSYNOct 4, 2023